Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prostate Cancer Genetic Risk Evaluation and Screening Study
Sponsor: Massachusetts General Hospital
Summary
This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations, family history, or Black/African ancestry and evaluate the utility of prostate MRI as a screening tool. The hypothesis is that this targeted population of men are at elevated risk of developing prostate cancer compared to the general population, and enhanced screening with MRI will enable early detection and diagnosis of potentially aggressive prostate cancer, characterization of the penetrance of specific mutations, and potentially identify new genetic risk mutations.
Official title: Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)
Key Details
Gender
MALE
Age Range
35 Years - 74 Years
Study Type
OBSERVATIONAL
Enrollment
400
Start Date
2020-02-12
Completion Date
2040-12
Last Updated
2024-10-09
Healthy Volunteers
No
Conditions
Interventions
Prostate cancer screening
Physical exam (digital rectal exam), prostate-specific antigen (PSA) and PSA derivatives, and multiparametric MRI of the prostate
Locations (1)
Massachusetts General Hospital
Boston, Massachusetts, United States